anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The SHIP cohort study was launched in 2006 for the purpose of improving healthy life expectancy in patients with any cardiovascular diseases (CVD) who were admitted to the Sakakibara Heart Institute. The study used a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD including cancers, via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year. Organ sites of cancers were also identified whenever possible. The study sorted any diagnoses of CVD into nine categories, namely coronary artery diseases, aortic diseases, peripheral artery diseases, myocardial diseases, unclassified or any-cause heart failure, valvular heart diseases, arrhythmias, congenital CVD, and others. For example, if a patient had a couple of diseases, he or she had a plural category. Cerebrovascular diseases were included in the category of 'others' because of the mixed cause for the diseases such as embolic strokes, lacunar infarction, cardio-embolic strokes, and hemorrhagic strokes, etc. Atherosclerotic CVD were defined by the presence of one or more of the following three diseases: coronary artery diseases, aortic diseases and peripheral artery diseases. With regard to the detail of coronary artery diseases, there were acute coronary syndromes, previous myocardial infarction and stable ischemic heart diseases. Aortic diseases consisted of acute aortic syndromes and aortic aneurysms. Non-atherosclerotic CVD were defined as any CVD except atherosclerotic and congenital CVD. The SHIP cohort study also handled to define lifestyle related diseases when confirmed a diagnosis of one or more of the presence of hypertension, dyslipidemia, diabetes mellitus and chronic kidney disease in accordance with the universal criteria. A history of tobacco smoking was also identified. Among a total of 36,151 patients with any CVD enrolled in the SHIP cohort study between June 2006 and July 2014, we excluded 245 patients who had already been diagnosed with any cancers at the time of enrollment in the SHIP cohort study, and 3,811 patients with congenital CVD including Marfan syndrome. Thus, we analyzed a total of 32,095 consecutive patients with acquired CVD in the present study.Our study was conducted in two steps to assess an incidence of cancers in patients with acquired CVD. The first step consisted of a comparison between those with atherosclerotic CVD and non-atherosclerotic CVD with regard to an incidence of cancers. The second step determined the association between a singular presence versus a plural presence of atherosclerotic CVD and an incidence of cancers.
BACKGROUND: This study aims to construct a model predicting the probability of RF in AECOPD patients upon hospital admission.
METHODS: This study retrospectively extracted data from MIMIC-IV database, ultimately including 3776 AECOPD patients. The patients were randomly divided into a training set (n = 2643) and a validation set (n = 1133) in a 7:3 ratio. First, LASSO regression analysis was used to optimize variable selection by running a tenfold k-cyclic coordinate descent. Subsequently, a multifactorial Cox regression analysis was employed to establish a predictive model. Thirdly, the model was validated using ROC curves, Harrell's C-index, calibration plots, DCA, and K-M curve.
RESULT: Eight predictive indicators were selected, including blood urea nitrogen, prothrombin time, white blood cell count, heart rate, the presence of comorbid interstitial lung disease, heart failure, and the use of antibiotics and bronchodilators. The model constructed with these 8 predictors demonstrated good predictive capabilities, with ROC curve areas under the curve (AUC) of 0.858 (0.836-0.881), 0.773 (0.746-0.799), 0.736 (0.701-0.771) within 3, 7, and 14 days in the training set, respectively and the C-index was 0.743 (0.723-0.763). Additionally, calibration plots indicated strong consistency between predicted and observed values. DCA analysis demonstrated favorable clinical utility. The K-M curve indicated the model's good reliability, revealed a significantly higher RF occurrence probability in the high-risk group than that in the low-risk group (P < 0.0001).
CONCLUSION: The nomogram can provide valuable guidance for clinical practitioners to early predict the probability of RF occurrence in AECOPD patients, take relevant measures, prevent RF, and improve patient outcomes.
Young adult drivers with Attention Deficit Hyperactivity Disorder (ADHD) will be compared on a driving simulator after taking PRC-063 or LDX in a repeated-measure, randomized, doubleblind, crossover study design. Each subject will be randomized to receive up to a 21-day course of PRC-063 followed by up to a 21 day course of LDX or vice versa. There will be no washout between treatments. On days 1 through 7, subjects will receive the lowest dose (45 mg of PRC-063 or 30 mg of LDX) of study medication. On days 8 through 14, subjects will receive the middle dose (70 mg of PRC-063 or 50 mg of LDX). On days 15 through 21, subjects will receive the highest dose (100 mg of PRC-063 or 70 mg of LDX). During Days 1 through 21, if a subject is responding satisfactorily to medication, he or she may remain on that daily dose. Driving laboratory testing will be conducted between Day 17 and Day 21. Following the laboratory testing, the subject will begin a second titration of the alternate treatment, starting on Day 22 through Day 28 at the lowest dose (45 mg of PRC-063 or 30 mg of LDX) of study medication, Day 29 through Day 35 on the middle dose (70 mg of PRC-063 or 50 mg of LDX) and Day 36 through Day 42 on the highest dose (100 mg of PRC-063 or 70 mg of LDX). During Days 22 through 42, if a subject is responding satisfactorily to medication, he or she may remain on that daily dose. Following titration with the second treatment, subjects will attend a second driving laboratory testing, conducted between Day 38 to Day 42. Subjects will subsequently attend a safety and study termination visit.
Recent findings in glycobiology revealed direct evidence of the involvement of oligosaccharide changes in human diseases, including liver diseases. Fucosylation describes the attachment of a fucose residue to a glycan or glycolipid. We demonstrated that fucosylated proteins are useful serum biomarkers for nonalcoholic fatty liver disease. Among fucosyltransferases, expression of alpha-1, 6-fucosyltransferase (Fut8), which produces core fucose, is frequently elevated during the progression of human chronic liver diseases. Previously, we discovered core-fucose-specific Pholiota squarrosa lectin (PhoSL) from Japanese mushroom Sugitake. Lectins are bioactive compounds that bind to glycan specifically, and various kinds of lectin have a variety of biological functions. Using high-fat and high-cholesterol (HFHC)-fed steatohepatitic mice, we found that core fucosylation increases in hepatic inflammatory macrophages. Antibody drugs bind to specific antigens and block protein function. We hypothesized that, like antibody drugs, PhoSL could have inhibitory effects on glycoproteins involved in steatohepatitis progression. PhoSL administration dramatically decreased hepatic macrophage infiltration and liver fibrosis-related gene expression. Using mouse macrophage-like cell RAW264.7, we found that PhoSL enhanced core-fucose-mediated activation of macrophage cell death by blocking interferon-γ/signal transducer and activator of transcription 1 (STAT1) signaling. Core-fucose-mediated cell death is a mechanism for the anti-inflammatory effects and anti-fibrotic effects of PhoSL on activated macrophages in steatohepatitic liver. In addition, PhoSL provides an anti-fibrotic effect by blocking transforming growth factor-β/SMAD family member 3 signaling in hepatic stellate cells. In conclusion, we found core-fucose-specific PhoSL administration could suppress steatohepatitis progression by decreasing inflammatory macrophage infiltration and fibrotic signaling in hepatic stellate cells.
BACKGROUND: Alport syndrome is a genetic disorder caused by mutations in the COL4A5 gene, which encodes type IV collagen α5 chain, leading to chronic nephritis, hearing loss, and ocular abnormalities. Recent reports suggest this genetic mutation may also increase the risk of cerebral aneurysms and fibromuscular dysplasia, indicating a potential association with vascular vulnerability.
CASE PRESENTATION: A 66-year-old woman was admitted with recurrent transient weakness of the left hand, which had gradually worsened in duration over three months. Her medical history included chronic nephritis since childhood. Her two sons had end-stage renal disease and hearing loss since their 20s, and her mother also had chronic kidney disease and hearing loss. One son had a history of traumatic subarachnoid hemorrhage, and the other had spinal epidural hematoma. On admission, she had reduced renal function with proteinuria, acute cerebral infarction in the subcortical white matter of the right fronto-parietal and parieto-occipital lobes, and multiple intracranial arterial stenoses (ICAS), including the right middle and right posterior cerebral artery. Vessel wall imaging of the right middle cerebral artery showed a concentric stenotic pattern. Genetic tests identified a pathogenic missense mutation in exon 24 of COL4A5 (exon 24:c.G1700 >C: p.(Gly567Arg)) that was heterozygous for the patient and hemizygous for her son. She was diagnosed with Alport syndrome.
CONCLUSION: It is important to consider Alport syndrome as a possible cause of ICAS in patients with a family history of renal failure or hearing loss and to conduct a genetic analysis of type IV collagen genes.
PURPOSE: A composition containing complex medicinal herb extract as an active ingredient is provided to suppress topical allergic reaction and general allergic reaction and prevent and treat allergic disease. CONSTITUTION: A pharmaceutical composition for preventing and treating allergic disease contains medicinal herb mixture extract of Rosin, Angelica dahurica and Phellodendri Cortex as an active ingredient in 1~15: 1~10: 1~10 of weight ratio(w/w). The medicinal herb extract is isolated using water, low alcohol of 1-4 carbon atoms or their mixture. The allergy is anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergy, or food allergy. A functional health food for preventing and relieving allergic disease contains the medicinal herb complex extract as an active ingredient. The functional health food is used in the form of powder, granule, tablet, capsule or beverage.
The invention relates to a forest leech (Haemadipsa sylvestris) antithrombotic peptide Sylvestrin and a gene and application thereof, belonging to the technical field of biomedicine. The forest leech antithrombotic peptide Sylvestin is a single-chain polypeptide encoded by a forest leech analgesic peptide gene, and has the molecular weight of 4790.5 daltons and the isoelectric point of 6.28. The forest leech antithrombotic peptide Sylvestin consists of an amino acid sequence shown in SEQ ID NO. 1. The gene for coding the forest leech antithrombotic peptide Sylvestin consists of a nucleotide sequence shown in SEQ ID NO. 2. The forest leech antithrombotic peptide Sylvestin can inhibit FXIIa and kallikrein, and has extremely obvious antithrombotic and acute cerebral hemorrhage inhibiting effects; the antithrombotic peptide has simple structure, convenient artificial synthesis and strong antithrombotic activity, and can be used for preparing FXIIa and kallikrein inhibitors and medicines for resisting thrombosis and inhibiting acute cerebral hemorrhage.
Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
DMT nicotinate and DMT pamoate are disclosed. DMT and its salts are found useful in the treatment of stroke, multiple sclerosis, Parkinson's disease, and traumatic brain injury. They are particularly useful in the treatment of haemorrhagic stroke. They are particularly useful in the immediate treatment of undiagnosed stroke. They are for use with anti-hypertensives when treating haemorrhagic stroke or TBI. Also taught are preferred dosages and serum levels of DMT, an intravenous pump device containing a pharmaceutically acceptable form of DMT. The pump may be configured to provide a specific dose and/or duration. The pump may have a locking system to prevent access to said compound or said DMT above the dose.
Double compounds of theophylline with water-soluble salts of m-hydroxybenzoic acid are prepared by interaction of the components in the presence of a solvent such as water.  The products possess therapeutic properties.  The process may be effected by (1) reacting 1 mol. of theophylline with 2 mols. of an alkali metal salt or 1 mol. of the neutral magnesium salt of m-hydroxybenzoic acid; (2) treating 1 mol. of theophylline with 2 mols. of m-hydroxybenzoic acid and adding sufficient alkali metal or magnesium hydroxide to give a neutral product; (3) reacting 1 mol. of an alkali metal compound of theophylline with 1 mol. of an alkali metal salt of m-hydroxybenzoic acid and 1 mol. of the free acid, or with 2 mols. of an alkali metal salt of the acid with the addition of one equivalent of a stronger acid.  An example is given.
Recent observations have revealed upregulation of H3K27cr in colorectal cancer (CRC) tissues; however, the underlying cause remains elusive. This study aimed to investigate the mechanism of H3K27cr upregulation and its roles in CRC metastasis. Clinically, our findings showed that H3K27cr served as a highly accurate diagnostic marker to distinguish CRC tissues from healthy controls. Elevated levels of LINC00887 and H3K27cr were associated with a poorer prognosis in CRC patients. Functionally, LINC00887 and H3K27cr facilitated the migration and invasion of CRC cells. Mechanistically, LINC00887 interacted with SIRT3 protein. Overexpressed of LINC00887 obstructed the enrichment of SIRT3 within GCN5 promoter, thereby elevating H3K27ac but not H3K27cr level within this region, subsequently activating GCN5 expression. This activation increased the global level of H3K27cr, promoting the enrichment of GCN5, H3K27cr, and YEATS2 within ETS1 promoter, activating ETS1 transcription and ultimately promoting the metastasis of CRC. The in vivo study demonstrated that inhibition of LINC00887 suppressed CRC metastasis, but this inhibitory effect was nullified when mice were treated with NaCr. In conclusion, our results confirmed the diagnostic biomarker potential of H3K27cr in individuals with CRC, and proposed a functional model to elucidate the involvement of LINC00887 in promoting CRC metastasis by elevating H3K27cr level.
Various techniques are disclosed to provide for improved human body temperature detection using thermal images of an inner canthus. In one example, a method includes capturing a thermal image of a human being using a thermal imager. The method also includes detecting a face and an inner canthus of the human being in the thermal image using an artificial neural network. The method also includes determining a temperature measurement of the inner canthus using corresponding pixels of the thermal image. The method also includes determining a body temperature of the human being using the temperature measurement. Additional methods and systems are also provided.
[Problem] To elucidate the mechanism of an anti-tumor effect of a ketogenic diet therapy to discover a novel cancer treatment method. [Solution] Provided is a composition for treating cancer, the composition comprising a ketogenic diet therapy composition and is used in combination with an inflammatory cytokine inhibitor. Also provided is a novel cancer immunotherapy comprising a combination of the administration of an inflammatory cytokine inhibitor and a ketogenic diet therapy. The ketogenic diet therapy composition is a composition containing a fat in an amount of 55% or more. The inflammatory cytokine inhibitor is preferably an IL-1 inhibitor, an IL-6 inhibitor or a TNF-α inhibitor. When used in combination with the inflammatory cytokine inhibitor, the anti-tumor effect of the ketogenic diet therapy is enhanced.
INTRODUCTION: Low socioeconomic status (SES) has been linked to chronic pain (CP); however, the mechanisms by which SES over the life course influences downstream CP outcomes remain unclear.
METHODS: This study utilizes data from the Midlife in the United States (MIDUS) survey, a prospective sample of community-dwelling individuals (N=781), to investigate the chain of risk additive model of SES in relation to CP. Additionally, the study examines the mediating role of allostatic load (AL) in the relationship between life course SES and CP. Confirmatory factor analysis was employed to capture the multidimensionality of life course SES and path analysis was used to examine the direct and indirect effects on CP. AL was computed by quartile-based summation and by latent class analysis.
RESULTS: Results indicated lower SES in MIDUS 2 was associated with greater high-interference CP odds in MIDUS 3 (OR=1.069, 95% CI=1.006-1.136, P < 0.05) and no association was found between distal SES and levels of CP interference. Similarly, no significant relationship was observed between SES and the number of CP locations. Additionally, no additive effects of SES were found, and AL did not present mediation effects on the association between life course SES and CP.
DISCUSSION: The present study emphasizes the importance of directly proximal effects of SES on CP, underscoring the need for equitable distribution of health resources and the implementation of policies focused on diminishing socioeconomic inequalities. Further research is needed to examine alternative pathways by which proximal SES impact CP.
Participants will receive a single 1000-mg/m\^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
The present invention is inter alia directed to syringes suitable for compositions comprising RNA, preferably RNA formulated in lipid-based carriers. In particular, kit or kit of parts comprising said suitable syringes are provided. The invention also relates to pre-filled syringes containing pharmaceutical compositions comprising RNA, preferably RNA formulated in lipid-based carriers. Also provided are methods of treating or preventing disorders or diseases, and first and second medical uses. Further the invention is directed to different analytic methods for determining the suitability of syringes for compositions comprising RNA and for detecting RNA agglomerations. Moreover, uses of suitable syringes e.g. for reducing or preventing RNA agglomeration, are described.
The invention relates to an etoricoxib oral microemulsion preparation and a preparation method thereof. The etoricoxib oral microemulsion preparation comprises the following components in percentage by weight: 1-3% of etoricoxib, 3-10% of oil phase, 3-10% of emulsifier, 3-10% of co-emulsifier, 0-0.2% of sweetening agent, 0-0.5% of essence, 0.1-0.5% of preservative and 70-90% of water. The preparation method comprises the following steps: firstly, adding the etoricoxib in the oil phase and dissolving; secondly, adding the emulsifier and the co-emulsifier in the oil phase to form crude emulsion; and finally, transferring the crude emulsion into a high-pressure homogenizer, adding water, and homogenizing under high pressure to obtain the microemulsion preparation. Oil-in-water type microemulsion liquid drops wrap the etoricoxib, bad taste of medicines is improved, the problem that the etoricoxib is difficultly dissolved into water is solved, dissolution is improved, and bioavailability is also improved. In addition, through addition of the sweetening agent and the essence, medication compliance of a patient is improved. Raw materials used in the preparation do not need to be subjected to special treatment, special equipment is not required, the preparation method is easy to operate, quality of products is stable, and the etoricoxib oral microemulsion preparation is suitable for large-scale production.
T-DXd 5.4 mg/kg and Durvalumab 1500 mg were infused intravenously once 3 weeks, and Capecitabine 750 mg/m2 was administered orally twice daily for 14 days with a 7-day rest period. T-DXd, Capecitabine, and Durvalumab were repeated 3 cycles preoperatively and 3 cycles postoperatively, followed by 10 cycles of Durvalumab monotherapy every 4 weeks.
This study is an open labeled, parallel group, and randomization study. At 7 days after mitral valve repair, bioprosthetic MV or AV replacement surgery, warfarin or edoxaban will be started per oral route. All study patients started to receive bridging therapy with parenteral anti-coagulant (UFH) according to local practice before switching to warfarin or edoxaban. Among patients who take warfarin, international normalized ratio will be used to monitor the effectiveness of the anticoagulant warfarin as usual daily practice. All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period. Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd ( creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors). Both drugs will be maintained for 3 months. During study period, all patients will be carefully monitored for thromboembolic events including valve dysfunction, and stroke or bleeding complication. At 3 months after surgery, 3 dimensional CT scan and echocardiography will be performed for detecting valvular dysfunction, any thrombus or bleeding in heart \& lung.
Asthma is a chronic respiratory condition characterized by eosinophilic airway inflammation. Individuals with classic asthma experience paroxysmal symptoms including cough, wheeze, shortness of breath and chest tightness. Cough variant asthma (CVA) is asthma in which chronic cough (cough lasting eight weeks or more) is the sole or predominant symptom of asthma. The pathophysiologic mechanisms which differentiate asthma, CVA, and eosinophilic bronchitis without asthma are not fully understood. We have recently identified individuals with chronic cough who cough during methacholine but have normal airway sensitivity (ie. do not have asthma or CVA) (COUGH) and may or may not have eosinophilic bronchitis. The purpose of this research is to further explore the pathophysiologic basis for cough in these conditions using two 'indirect' inhalation challenge tests: eucapneic voluntary hyperventilation (EVH) and Mannitol), which induce osmotic and/or temperature changes in airway. Specifically, this study will collect preliminary data on the sensory-mechanical responses of individuals with CVA, COUGH and healthy controls to EVH and Mannitol Challenges.